From: Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer
DNA methylation combination | Body fluid | Method | Number of cases | Number of controls | Sensitivity%/specificity% or main findings | References |
---|---|---|---|---|---|---|
RASSF1A/RARB2 | Plasma/csbDNA | qMSP | 60 | 32 | 87/75 | [78] |
SHOX2/PTGER4 | plasma | Rt-PCR | 117 | 122 | 67/90 or 90/73 | [77] |
RTEL1/PCDHGB6 | cfDNA | qMSP-PCR | 70 | 80 | 62.9/90 (AUC0.755) | [17] |
HOXD10/PAX9/PTPRN2/STAG3 | serum | MSRE/qPCR | 23 | 23 | 87.8/90.2 | [109] |
APC/RASSF1A/CDH13/KLK1/DLEC1 | plasma | MSP | 110 | 50 | 83/70 | [47] |
APC/AIM1/CDH1/DCC/MGMT/RASSF1A | serum | qMSP | 76 | 30 | 84/57 | [79] |
DAPK/PAX5b/PAX5a/Dal1/GATA5/SULF2/CXCL14 | sputum | MSP | 40 | 90 | 75/68 | [56] |
MGMT/DAPK/PAX5β/Dal-1/PCDH20/Jph3/Kif1a | 64 | 64 | ||||
CSF3R/ERCC1 | peripheral leukocyte | pyrosequencing | 138 | 138 | Predict higher risk for SCLC | [55] |
CDH1/p16/MGMT/DAPK | peripheral lymphocyte | MSP | 49 | 22 | methylation of CDH1 and DAPK occurs in the early stages LC | [53] |
methylation of p16 and MGMT occurs in later stages LC | ||||||
p16/RASSF1A/FHIT/RTL | WBC DNA | SYBR Green-based qMSP and qPCR | 200 | 200 | AUC 0.670–0.810 | [54] |